BAY 2862789
Alternative Names: BAY-2862789Latest Information Update: 24 Aug 2023
At a glance
- Originator Bayer
- Class Antineoplastics; Small molecules
- Mechanism of Action Diacylglycerol kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Cancer
Most Recent Events
- 07 Aug 2023 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA, Israel (PO) (NCT05858164)
- 16 May 2023 Bayer plans a phase I trial for Solid tumors and Non-small cell lung cancer (Late-stage disease) in USA and Israel (PO) in May 2023 (NCT05858164)
- 20 Jan 2023 Preclinical trials in Cancer in Germany (unspecified route) in January 2023 (Bayer pipeline, January 2023)